In today’s scientific era, molecular research has paved the way
for the development of pharmaceuticals that are improving the lives of millions
of patients. The discovery of the human immunodeficiency retrovirus as the
causative agent of AIDS led to the development of reverse transcriptase inhibitors
such as zidovudine. Monoclonal antibodies directed against tumor necrosis
factor α have changed the lives of many patients with rheumatoid arthritis.
Imatinib mesylate, a specific inhibitor of the bcr-abl protein kinase, has
transformed the prognosis for patients with chronic myeloid leukemia; and
as drug-resistant variants arise, DNA sequencing can identify the mutations
responsible and provide a rational basis for further drug development.1,2 In 2004 the first angiogenesis inhibitors
were approved by the US Food and Drug Administration, in one case for treatment
of metastatic colorectal cancer and in another for age-related macular degeneration.3,4 There is reason for optimism that this
is just the beginning, and that the huge investments in molecular biology
and genomics research made 10 to 30 years ago will provide an increasingly
robust flow of new and effective medicines.
A, Source: Office of Extramural Research, National Institutes of Health.
B, Fields included are anatomy; biochemistry; biology; biomedical engineering;
biophysics; cell and molecular biology; genetics, microbiology, immunology,
and virology; nutrition; pathology; pharmacology; physiology; zoology and
other biosciences. Source: Survey of Graduate Students and Postdoctorates
in Science and Engineering via WebCASPAR, National Science Foundation. C,
Source: Survey of Graduate Students and Postdoctorates in Science and Engineering
via WebCASPAR, National Science Foundation. B, C reproduced with permission.12
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 15
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.